Suraksha Diagnostic Limited (NSE:SURAKSHA)
India · Delayed Price · Currency is INR 303.70
+2.90 (0.96%)
Sep 8, 2025, 3:30 PM IST
Suraksha Diagnostic Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 2,637 | 2,521 | 2,187 | 1,901 | 2,232 | 1,400 | |
Revenue Growth (YoY) | 18.41% | 15.26% | 15.03% | -14.81% | 59.42% | - |
Cost of Revenue | 398.34 | 377.21 | 354.02 | 371.17 | 700.89 | 329.04 |
Gross Profit | 2,239 | 2,144 | 1,833 | 1,530 | 1,531 | 1,071 |
Selling, General & Admin | 534.54 | 510.59 | 459.7 | 481.69 | 403.37 | 396.15 |
Other Operating Expenses | 845.43 | 792.95 | 645.88 | 584.9 | 486.74 | 427.07 |
Operating Expenses | 1,741 | 1,660 | 1,436 | 1,383 | 1,174 | 980.34 |
Operating Income | 497.83 | 483.86 | 397.48 | 146.87 | 356.98 | 90.69 |
Interest Expense | -88.75 | -83.85 | -87.88 | -90.6 | -88.46 | -15.6 |
Interest & Investment Income | 32.45 | 32.45 | 32.2 | 25.37 | 17.17 | 6.11 |
Currency Exchange Gain (Loss) | - | - | - | - | - | -0.6 |
Other Non Operating Income (Expenses) | 3.71 | 3.71 | 3.31 | 4.25 | 3.01 | 1.33 |
EBT Excluding Unusual Items | 445.24 | 436.17 | 345.11 | 85.89 | 288.7 | 81.93 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.09 | 2.94 |
Gain (Loss) on Sale of Assets | -2.56 | -2.56 | -21.45 | -24.32 | -14.15 | -24.5 |
Asset Writedown | -11.37 | -21.86 | -9.13 | - | - | - |
Other Unusual Items | 2.3 | 2.3 | - | 5.91 | 3.71 | 3.37 |
Pretax Income | 433.61 | 414.05 | 314.53 | 67.48 | 278.35 | 63.74 |
Income Tax Expense | 108.75 | 104.27 | 83.26 | 6.83 | 70.11 | -0.61 |
Earnings From Continuing Operations | 324.86 | 309.78 | 231.26 | 60.65 | 208.24 | 64.35 |
Minority Interest in Earnings | 7.96 | 8.46 | 4.99 | 4.51 | - | - |
Net Income | 332.83 | 318.24 | 236.25 | 65.16 | 208.24 | 64.35 |
Net Income to Common | 332.83 | 318.24 | 236.25 | 65.16 | 208.24 | 64.35 |
Net Income Growth | 31.35% | 34.70% | 262.57% | -68.71% | 223.60% | - |
Shares Outstanding (Basic) | 52 | 52 | 53 | 53 | 53 | 43 |
Shares Outstanding (Diluted) | 52 | 52 | 53 | 53 | 53 | 53 |
Shares Change (YoY) | -2.84% | -2.29% | - | - | -0.02% | - |
EPS (Basic) | 6.42 | 6.11 | 4.43 | 1.22 | 3.91 | 1.49 |
EPS (Diluted) | 6.28 | 5.97 | 4.43 | 1.22 | 3.91 | 1.21 |
EPS Growth | 32.26% | 34.76% | 263.12% | -68.77% | 223.61% | - |
Free Cash Flow | - | 213.35 | 150.09 | 309.29 | 385.74 | 81.11 |
Free Cash Flow Per Share | - | 4.10 | 2.82 | 5.80 | 7.24 | 1.52 |
Gross Margin | 84.90% | 85.04% | 83.81% | 80.48% | 68.60% | 76.50% |
Operating Margin | 18.88% | 19.19% | 18.17% | 7.72% | 15.99% | 6.48% |
Profit Margin | 12.62% | 12.62% | 10.80% | 3.43% | 9.33% | 4.60% |
Free Cash Flow Margin | - | 8.46% | 6.86% | 16.27% | 17.28% | 5.79% |
EBITDA | 682.12 | 669.17 | 556.52 | 299.4 | 502.07 | 238.14 |
EBITDA Margin | 25.86% | 26.55% | 25.45% | 15.75% | 22.50% | 17.01% |
D&A For EBITDA | 184.3 | 185.31 | 159.04 | 152.53 | 145.09 | 147.46 |
EBIT | 497.83 | 483.86 | 397.48 | 146.87 | 356.98 | 90.69 |
EBIT Margin | 18.88% | 19.19% | 18.17% | 7.72% | 15.99% | 6.48% |
Effective Tax Rate | 25.08% | 25.18% | 26.47% | 10.12% | 25.19% | - |
Revenue as Reported | 2,676 | 2,559 | 2,223 | 1,937 | 2,258 | 1,414 |
Advertising Expenses | - | 40.42 | 34.01 | 44.4 | 28.22 | 15.42 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.